Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationWO1996013284 A1
Type de publicationDemande
Numéro de demandePCT/GB1995/002542
Date de publication9 mai 1996
Date de dépôt30 oct. 1995
Date de priorité28 oct. 1994
Numéro de publicationPCT/1995/2542, PCT/GB/1995/002542, PCT/GB/1995/02542, PCT/GB/95/002542, PCT/GB/95/02542, PCT/GB1995/002542, PCT/GB1995/02542, PCT/GB1995002542, PCT/GB199502542, PCT/GB95/002542, PCT/GB95/02542, PCT/GB95002542, PCT/GB9502542, WO 1996/013284 A1, WO 1996013284 A1, WO 1996013284A1, WO 9613284 A1, WO 9613284A1, WO-A1-1996013284, WO-A1-9613284, WO1996/013284A1, WO1996013284 A1, WO1996013284A1, WO9613284 A1, WO9613284A1
InventeursYimin Qin, Keith Dennis Gilding
DéposantInnovative Technologies Limited
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes:  Patentscope, Espacenet
Wound treatment composition
WO 1996013284 A1
Résumé
A composition for use in treating a wound, e.g. cavity wounds, comprises a hydrogel containing O-carboxymethyl chitosan or N,O-carboxymethyl chitosan and a plasticising compound.
Revendications  (Le texte OCR peut contenir des erreurs.)
1. A composition for use in treating a wound comprising a hydrogel containing OCC or NOCC and a plasticising compound.
2. A composition as claimed in claim 1 containing a maximum of 5% by weight of
OCC and/or NOCC.
3. A composition as claimed in claim 2 containing 2-4% by weight OCC and/or
NOCC.
4. A composition as claimed in any one of claims 1 to 3 wherein the plasticiser is
present in an amount of less than 20% by weight.
5. A composition as claimed in any one of the preceding claims wherein the
plasticiser is a polyhydroxy compound.
6. A composition as claimed in claim 5 wherein the plasticiser is glycerol. sorbitol,
propylene glycol or polyethylene glycol.
7. A composition as claimed in any one of the preceding claims wherein the
aqueous phase of the gel comprises isotonic buffered saline.
8. A composition as claimed in any one of the preceding claims additionally
incorporating an anti-microbial agent.
9. A composition as claimed in claim 8 wherein the anti-microbial agent is
chlorhexidine gluconate.
10. A composition as claimed in any one of claims 1 to 8 incorporating glucose
oxidase/lactic acid hydrogenase enzymes.
11. A composition as claimed in any one of the preceding claims containing pectin
for wound debridement.
12. A composition as claimed in any one of the preceding claims having a viscosity
in the range 20,000 to 100.000 cP.
13. A composition as claimed in any one of the preceding claims which has been
sterilised by autoclaving.
14. A composition as claimed in any one of the preceding claims incorporated in a
delivery system.
15. The combination of a composition as claimed in any one of the preceding claims
and a film having a high MVTR capability.
16. The combination as claimed in claim 15 wherein the film has an MVTR of 3,000
to 12,000 g m"2 24hr"'.
Description  (Le texte OCR peut contenir des erreurs.)

WOUND TREATMENT COMPOSITION

The present invention relates to compositions which are useful in the treatment

of wounds. The invention relates more particularly to such compositions which

incorporate O-carboxymethyl chitosan (OCC) or N-, O- carboxymethyl chitosan

(NOCC) which are a water soluble derivatives of chitin.

NOCC is a known material and its preparation is disclosed for example in US-

A-4,619,995. Briefly NOCC may be prepared by a solid phase reaction between

chitosan and monochloroacetic acid under alkaline conditions. The degree of

substitution can be varied but is typically 0.6 to 1.0. OCC may be produced by a similar

procedure effected to give a degree of substitution of 0.3-0.5.

According to a first aspect of the present invention there is provided a

composition for use in treating a wound comprising a hydrogel containing OCC or

NOCC and a plasticising compound.

Compositions in accordance with the invention are useful in the treatment of

cavity wounds, e.g. decubitus ulcers. The compositions are introduced into the wound

and pressed firmly into the base thereof. For preference the wound is then covered and

sealed by a film having a high MVTR, typically 3,000 to 12.000 g m"2 24hr"' (e.g.

hydroderm (ex Wilshire Medical) or IT425 or IT625 (ex Innovative Technologies)).

The compositions may also be used in the treatment of sinuses.

Preferred compositions in accordance with the invention have a viscosity in the

range 20,000 to 100,000 cP. Compositions in accordance with the invention will generally contain a

maximum of 5% by weight of OCC and/or NOCC. Typically the OCC or NOCC

content will be in the range 2-4%.

The plasticiser will generally be present in a maximum amount of 20% by

weight, more usually in the range 2-20% by weight.

Examples of plasticiser include polyhydroxy compounds, e.g. glycerol, sorbitol,

propylene glycol, and polyethylene glycol (a preferred example of which is PEG 400).

The most preferred plasticiser glycerol.

The aqueous phase of the gel will for preference comprise isotonic buffered saline, e.g. phosphate buffered saline.

Additional components may be included in the composition to enhance their

healing properties. Examples include antimicrobial agents which may be used at a level

of 1-2% of the composition. A preferred anti-microbial agent is chlorhexidine

gluconate.

Antimicrobial properties may also be achieved by use of enzymes, e.g. glucose

oxidase/lactic acid peroxidase enzymes as a natural disinfection system activated by

glucose (present in exudate).

A further possibility is to include a component, e.g. pectin, which facilitates

wound debridement. This component may for example be used in an amount up to

20%, more preferably up to 10%, e.g. 0.05-1% by weight.

Compositions for use in accordance with the invention may be produced in

various ways. For example a composition may be produced by dissolving the required amounts of OCC or NOCC (e.g. 3-5%), plasticiser and any other components in

phosphate buffered saline at 90°C then cooling. The composition may be sterilised by

autoclaving at 120°C for 15 minutes.

The gels obtained may be incorporated into a convenient delivery system, e.g. a

syringe, sachet, tube or squeeze bottle, for introduction into a wound.

The invention is illustrated by the following non-limiting Example.

Example

A gel was produced by dissolving 3-4% NOCC and 1 -2% high methoxy pectin

(Bulmers) in isotonic phosphate buffered saline at pH 7 with 2% glycerol. The gel was

filled into a vessel and autoclaved at 120°C for 15 minutes. The viscosity of the gel

reduced slightly during autoclaving but by no more than 10%.

Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
EP0356060A2 *7 août 198928 févr. 1990Minnesota Mining And Manufacturing CompanyWound filling compositions
EP0426368A2 *24 oct. 19908 mai 1991Howmedica Inc.Compositions containing derivatives of chitin for preventing adhesion
US3903268 *19 févr. 19712 sept. 1975Lescarden LtdChitin and chitin derivatives for promoting wound healing
US4659700 *2 mars 198421 avr. 1987Johnson & Johnson Products, Inc.Chitosan-glycerol-water gel
Citations hors brevets
Référence
1 *R.A.A.MUZZARELLI ET AL.: "N-CARBOXYBUTYL CHITOSAN AND FIBRIN GLUE IN CUTANEOUS REPAIR PROCESSES", JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS, vol. 5, no. 4, US, pages 396 - 410, XP000213548
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
WO1997003710A1 *19 juil. 19966 févr. 1997Innovative Technologies LimitedWound treatment composition
WO1998050050A1 *4 mai 199812 nov. 1998Chitogenics, Inc.Covalently linked n,o-carboxymethylchitosan and uses thereof
WO2006034688A1 *23 sept. 20056 avr. 2006Universität HamburgMethod for the production of a wound pad
WO2015061606A1 *23 oct. 201430 avr. 2015Medtronic Xomed, Inc.Chitosan stenting paste
US6124273 *13 oct. 199726 sept. 2000Chitogenics, Inc.Chitin hydrogels, methods of their production and use
US664594720 mai 199911 nov. 2003Chitogenics, Inc.Adhesive N, O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins
US68090856 juil. 200026 oct. 2004Chitogenics, Inc.Adherent N,O-Carboxymethylchitosan drug delivery devices for moist tissue and methods of their use
US6894035 *25 sept. 200317 mai 2005Chitogenics, Inc.Adhesive N,O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins
US7238678 *11 avr. 20053 juil. 2007Chitogenics, Inc.Adhesive N,O-carboxymethylchitosan coatings which inhibit attachment of substrate-dependent cells and proteins
US726509720 août 20024 sept. 2007Chitogenics, Inc.Methods of drug delivery using sulphated chitinous polymers
US919257430 juin 201424 nov. 2015Medtronic Xomed, Inc.Chitosan paste wound dressing
US919269224 oct. 201324 nov. 2015Medtronic Xomed, Inc.Chitosan stenting paste
Classifications
Classification internationaleA61L26/00, A61L15/28
Classification coopérativeA61L15/28, A61L26/0023
Classification européenneA61L15/28, A61L26/00B5
Événements juridiques
DateCodeÉvénementDescription
9 mai 1996AKDesignated states
Kind code of ref document: A1
Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN
9 mai 1996ALDesignated countries for regional patents
Kind code of ref document: A1
Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
27 juin 1996DFPERequest for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
7 août 1996121Ep: the epo has been informed by wipo that ep was designated in this application
23 juil. 1997122Ep: pct application non-entry in european phase
25 sept. 1997REGReference to national code
Ref country code: DE
Ref legal event code: 8642